hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06278961 id: IRB 2021-4329 briefTitle: Families Filming Infants Learning Movement acronym: FILM overallStatus: RECRUITING date: 2021-01-28 date: 2024-09-30 date: 2024-09-30 date: 2024-02-26 date: 2024-02-26 name: Ann & Robert H Lurie Children's Hospital of Chicago class: OTHER name: Northwestern University name: IRCCS Fondazione Stella Maris name: University of Melbourne name: University of Sydney briefSummary: The study objective is to improve accuracy in the early detection of neurodevelopmental impairment, especially CP, by evaluating the timepoint (in weeks post term age) that the Prechtl GMA is most useful for prediction of neurodevelopmental impairment at two years of age in children with and without medical complexity. The study team plans to recruit 100 healthy, term-born infants and 250 infants at risk of developing CP for a total of 350 enrolled infants. conditions: Infant Development conditions: Cerebral Palsy conditions: Motor Disorders conditions: Neurological Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 350 type: ESTIMATED name: Observational measure: Fidgety Movements in healthy, term born infants measure: Fidgety Movements in children with a range of medical complexities measure: Fidgety Movements and two-year Neurodevelopmental outcomes in health, term born infants measure: Fidgety Movements and two-year Neurodevelopmental outcomes in children with a range of medical complexities sex: ALL minimumAge: 10 Weeks maximumAge: 20 Weeks stdAges: CHILD facility: Feinberg School of Physical Therapy and Human Movement Sciences status: RECRUITING city: Chicago state: Illinois zip: 60611 country: United States name: Ryan Millman, B.S. role: CONTACT phone: 847-530-2319 email: ryan.millman@northwestern.edu lat: 41.85003 lon: -87.65005 hasResults: False
nctId: NCT06278948 id: LRP23023-depigmenting cream briefTitle: Efficacy and Tolerability of Test Product Versus Cysteamine 5% in Treatment of Facial Epidermal Melasma overallStatus: RECRUITING date: 2023-10-06 date: 2024-06 date: 2024-06 date: 2024-02-26 date: 2024-02-26 name: Cosmetique Active International class: INDUSTRY briefSummary: This interventional, randomized, investigator blinded, controlled study conducted in one centre consists in a 4-month evaluation period within the same season avoiding sunny season on 140 subjects with facial epidermal melasma. conditions: Melasma studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 140 type: ESTIMATED name: Group TP name: Group CYS measure: change in mMASI scoring measure: change in Investigator's Global Assessment (IGA) measure: change in Subject Global Assessment of Improvement (SGAI) sex: ALL minimumAge: 20 Years maximumAge: 50 Years stdAges: ADULT facility: MS Clinical Research Pvt. Ltd status: RECRUITING city: Bangalore country: India lat: 12.97194 lon: 77.59369 hasResults: False
nctId: NCT06278935 id: APP-24-00887 briefTitle: Lifestyle Tailored Offloading for Diabetic Foot Ulcers overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-04 date: 2026-04 date: 2024-02-26 date: 2024-04-02 name: University of Southern California class: OTHER briefSummary: The goal of this pilot clinical trial is to develop and test a tailored occupational therapist-led lifestyle-focused intervention to aid patients in improving diabetic foot ulcer care. The main questions it aims to answer are to determine the acceptability and feasibility of taking a tailored lifestyle-focused approach as part of comprehensive diabetic foot ulcer management. Patient participants with DFUs who require offloading treatment will receive the tailored lifestyle-focused self-management intervention. conditions: Diabetic Foot Ulcer conditions: Diabetic Foot studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Lifestyle-based intervention by a occupational therapist measure: Participant satisfaction measure: Diabetes distress measure: Factors affecting offloading treatment measure: DFU-related outcomes sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06278909 id: 6036699 briefTitle: Trigeminal Nerve Stimulation in Treatment-resistant Generalized Anxiety Disorder: a Feasibility Study overallStatus: RECRUITING date: 2024-01-18 date: 2025-01-30 date: 2025-06-30 date: 2024-02-26 date: 2024-03-26 name: Dr. Rafael Freire class: OTHER briefSummary: This is a feasibility study for trigeminal nerve stimulation (TNS) in patients with treatment-resistant generalized anxiety disorder (TR-GAD). Ten participants will receive TNS for 8 weeks as an augmentation strategy to pharmacological treatment for generalized anxiety disorder (GAD).
Results from this study will inform a randomized controlled trial to be conducted in the future. conditions: Generalized Anxiety Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a traditional feasibility study, which evaluates preliminary safety and effectiveness information. It does not meet the definition of a "device feasibility" study. primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Trigeminal Nerve Stimulation measure: Incidence of treatment-emergent adverse events measure: Incidence of treatment-emergent side effects measured with the NSEC measure: Response to treatment defined by CGI-I score below 3 measure: Remission defined by CGI-S score below 3 measure: Change in anxiety severity measured by CGI-S measure: Change of anxiety symptoms measured with GAD-7 measure: Change of anxiety symptoms measured with PSWQ measure: Change of anxiety symptoms measured with BAI sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Kingston Health Sciences Centre status: RECRUITING city: Kingston state: Ontario country: Canada name: Yan Deng role: CONTACT phone: +1-613-548-7839 email: yan.deng@queensu.ca name: Rafael Freire, MD PhD role: PRINCIPAL_INVESTIGATOR name: Elisa Brietzke, MD PhD role: SUB_INVESTIGATOR name: Claudio Soares, MD PhD role: SUB_INVESTIGATOR lat: 44.22976 lon: -76.48101 hasResults: False
nctId: NCT06278896 id: 23-684-END briefTitle: Early Neutropenic Fever De-escalation of Antibiotics Study acronym: END overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2026-03-01 date: 2028-03-01 date: 2024-02-26 date: 2024-02-26 name: Brigham and Women's Hospital class: OTHER name: Dana-Farber Cancer Institute briefSummary: This is a randomized, open label clinical trial among individuals with hematologic conditions. The trial aims to evaluate the safety and clinical outcomes of de-escalating antibiotic therapy among stable individuals diagnosed with neutropenic fever, in which no bacterial infection has been identified. conditions: Hematologic Malignancy conditions: Febrile Neutropenia conditions: Antibiotic Stewardship studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 260 type: ESTIMATED name: Cessation of antibiotics measure: Mortality, transfer to the ICU, septic shock, culture-confirmed bacteremia measure: Antibiotic utilization measure: Mortality post F&N measure: Drug resistance measure: Clostridium difficile infection measure: Candidiasis measure: Adverse Events measure: Allergic Reactions measure: Bacteremia measure: Neutropenia measure: Length of stay measure: Readmissions measure: Fever sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06278883 id: Pro00115007 id: R01HG011794 type: NIH link: https://reporter.nih.gov/quickSearch/R01HG011794 briefTitle: Genomic Medicine Risk Assessment Care for Everyone - Implementation Phase acronym: GRACE overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-06-30 date: 2025-06-30 date: 2024-02-26 date: 2024-03-27 name: Duke University class: OTHER name: National Human Genome Research Institute (NHGRI) briefSummary: The "Genomic medicine Risk Assessment Care for Everyone" (GRACE)" intervention project will develop a scalable end-to-end solution for risk assessment and management that meets the needs of those populations living in low resource settings. The long-term goal is to increase access to and uptake of risk-informed evidence-based guidelines that will improve population health through better patient outcomes, higher quality of life, and decreased costs. The three primary aims are:
Patient participants will be asked to complete a baseline survey, enter their family health history information into MeTree (a family health history web-based platform) and complete a survey about their experience using the platform. Subsequent study procedures will depend on: 1) the results of their MeTree risk evaluation, 2) their acceptance/declination of genetic testing (for those categorized as needing testing by MeTree), and 3) the results of the test (for those accepting testing).
Blood relatives of the probands who are identified by the proband as open to engaging with the study will be contacted and offered genetic counseling and genetic testing. conditions: Cardiovascular Diseases conditions: Cancer conditions: Liver Diseases conditions: Hyperthermia studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Everyone who consents is enrolled in the risk assessment pipeline. primaryPurpose: SCREENING masking: NONE count: 750 type: ESTIMATED name: Disease Risk Assessment measure: Reach of genomic risk assessment measure: Utility of genomic risk assessment measure: Uptake of genetic counseling risk recommendations by the participant measure: Uptake of genetic testing recommendations by the provider sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UF Health Callahan city: Callahan state: Florida zip: 32011 country: United States lat: 30.56218 lon: -81.83066 facility: UF Health Murray Hill city: Jacksonville state: Florida zip: 32205 country: United States lat: 30.33218 lon: -81.65565 facility: UF Health Normandy city: Jacksonville state: Florida zip: 32221 country: United States lat: 30.33218 lon: -81.65565 facility: UF Health Kernan Square city: Jacksonville state: Florida zip: 32246 country: United States lat: 30.33218 lon: -81.65565 facility: UF Health Augustine Oaks city: Jacksonville state: Florida zip: 32258 country: United States lat: 30.33218 lon: -81.65565 hasResults: False
nctId: NCT06278870 id: SYSKY-2023-431-02 briefTitle: Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial overallStatus: RECRUITING date: 2023-09-06 date: 2031-06-30 date: 2031-06-30 date: 2024-02-26 date: 2024-02-26 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER briefSummary: The goal of this multicentre, randomized, double-blind controlled, phase III clinical trial is to compare the efficacy and safety of disitamab vedotin in combination with pyrotinib versus the standard first-line treatment of paclitaxel in combination with trastuzumab and pertuzumab (THP) for newly diagnosed recurrent/metastatic Human epidermal growth factor receptor 2 (HER2) positive advanced breast cancer, and to explore the impact of biomarkers on clinical efficacy and safety. The main questions it aims to answer are:
Participants in the experimental group will receive disitamab vedotin in combination with pyrotinib for 6-8 cycles (each cycle lasting 28 days), followed by maintenance treatment with trastuzumab in combination with pyrotinib. Participants in the control group will receive paclitaxel in combination with trastuzumab and pertuzumab for 6-8 cycles (each cycle lasting 21 days), followed by maintenance treatment with trastuzumab and pertuzumab.
Researchers will compare disitamab vedotin in combination with pyrotinib versus the standard first-line treatment of paclitaxel in combination with trastuzumab and pertuzumab to see if disitamab vedotin in combination with pyrotinib could be a new option for first-line treatment of HER2-positive metastatic breast cancer. conditions: HER2-positive Metastatic Breast Cancer conditions: First-line Treatment studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 312 type: ESTIMATED name: disitamab vedotin name: Pyrotinib name: trastuzumab name: Pertuzumab name: taxane drug measure: Progression Free Survival (PFS) measure: Overall Survival (OS) measure: Disease control rate (DCR) measure: Objective Response Rate (ORR) measure: Clinical Benefit rate (CBR) measure: Adverse Events (Based on CTCAE 5.0 standards) measure: Quality of Life (QoL) by Functional Assessment of Cancer Therapy for Breast Cancer (FACT-B) measure: Exploration of biomarkers sex: FEMALE minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sun Yat-sen Memorial Hospital,Sun Yat-sen University status: RECRUITING city: Guangzhou state: Guangdong zip: 510000 country: China name: Herui Yao, PhD role: CONTACT phone: +86 13500018020 email: yaoherui@mail.sysu.edu.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06278857 id: QCGC-001/2023 briefTitle: SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) acronym: SATELLITE overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-06-30 date: 2028-06-30 date: 2024-02-26 date: 2024-02-26 name: Queensland Centre for Gynaecological Cancer class: OTHER_GOV name: GlaxoSmithKline Research & Development Limited briefSummary: The main goal of this clinical trial is to evaluate dostarlimab, an immunotherapy drug, as a potential alternative to surgery for early-stage endometrial cancer with Mismatch Repair deficiency, a genetic cause for 20-30% of cases. The study aims to establish dostarlimab's efficacy and safety in early-stage endometrial cancer, exploring its potential as a non surgical option for those unsuitable or unwilling to undergo major surgery, allowing for fertility preservation or addressing specific health conditions.
nctId: NCT06278844 id: 3020 briefTitle: Exercise Capacity Improvement by Conduction System Pacing in heArt Failure patieNts Without Compelling CRT inDication acronym: ESCPAND overallStatus: RECRUITING date: 2023-12-12 date: 2026-09 date: 2027-12 date: 2024-02-26 date: 2024-02-26 name: University Hospital, Antwerp class: OTHER briefSummary: This randomized controlled trial aims to investigate the impact of conduction system pacing in comparison to right ventricular apical pacing on exercise capacity, as measured by peak oxygen uptake (VO2peak), in heart failure patients with indication for pacing but no compelling indication for cardiac resynchronization therapy (CRT). The mechanisms of exercise intolerance in heart failure patients influenced by conduction system pacing will be assessed. conditions: Heart Failure With Reduced Ejection Fraction conditions: Heart Failure With Preserved Ejection Fraction conditions: Heart Conduction Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 75 type: ESTIMATED name: Conduction system pacing name: Right ventricular apical pacing measure: Exercise capacity measure: Exercise capacity measure: Echocardiographic parameters (Ejection Fraction) measure: QRS width measure: Biomarker, N-terminal pro B-type natriuretic peptide levels measure: Health-related quality of life scores sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Universitair Ziekenhuis Antwerpen status: RECRUITING city: Edegem state: Antwerp zip: 2650 country: Belgium name: Faro Verelst role: CONTACT phone: 038213538 email: faro.verelst@uza.be lat: 51.15662 lon: 4.44504 hasResults: False
nctId: NCT06278831 id: 2023-02645 briefTitle: Efficacy of Structured SOcial COnsultation and Support in Reducing the FINancial Burden of Radiotherapy acronym: SOCOFIN-1 overallStatus: RECRUITING date: 2023-07-08 date: 2024-05-31 date: 2024-10-15 date: 2024-02-26 date: 2024-02-26 name: University Medical Center Goettingen class: OTHER briefSummary: Objectives:
To be assessed for eligibility: n = 300 To be allocated/randomised (if applicable) to trial: n = 150 To be analysed: n = 120 conditions: Financial Toxicity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 225 type: ESTIMATED name: Questionnaire measure: Financial Toxicity measure: Factors that may influence the occurrence or extent of financial burden measure: Factors that may influence the occurrence or extent of financial burden measure: Factors that may influence the occurrence or extent of financial burden measure: Factors that may influence the occurrence or extent of financial burden sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Medical Center Göttingen status: RECRUITING city: Göttingen state: Niedersachsen zip: 37075 country: Germany name: Rami El Shafie, Prof. Dr. role: CONTACT phone: +4955164505 email: rami.elshafie@med.uni-goettingen.de lat: 51.53443 lon: 9.93228 hasResults: False
nctId: NCT06278818 id: MNESYS-PE0000006 briefTitle: Effects of Telerehabilitation on Brain Network Connectivity overallStatus: RECRUITING date: 2023-12-07 date: 2024-06-07 date: 2026-03-01 date: 2024-02-26 date: 2024-02-26 name: University of Pavia class: OTHER name: University of Parma name: University of Bologna name: University of Rome Tor Vergata briefSummary: The current project aims at assessing the impact of various cognitive telerehabilitation approaches on patients with Mild Cognitive Impairment (MCI) associated with neurodegenerative diseases, namely Alzheimer's disease (AD) and Parkinson's disease (PD). The study focuses on non-pharmacological interventions to maintain patients' residual functionality, limit disease progression, and improve quality of life for both patients and their caregivers.
The study is designed to last 30 months, with follow-up assessments at three time points. The primary outcomes will be evaluated using rsFMRI and HD-EEG instrumental acquisitions, the secondary outcomes will be evaluated using clinical assessments and neuropsychological tests. conditions: Mild Cognitive Impairment studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: The neurophysiologist and neuroradiologist will be blinded to the type of rehabilitation treatment (experimental group vs. control). whoMasked: OUTCOMES_ASSESSOR count: 110 type: ESTIMATED name: Cognitive Telerehabilitation name: Control Condition measure: Changes in resting-state brain networks functional connectivity after NBTC treatment measure: Changes in resting-state EEG coherence after NBTC treatment measure: Changes in resting-state EEG coherence after HomeCore treatment measure: Changes in resting-state brain networks functional connectivity after SMRT treatment measure: Changes in neuropsychological and caregiver burden measures after TR sex: ALL minimumAge: 50 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Mondino Foundation status: RECRUITING city: Pavia zip: 27100 country: Italy name: Cristina Tassorelli, MD role: CONTACT phone: 0382380419 phoneExt: 0039 email: cristina.tassorelli@unipv.it name: Silvia Paola P Caminiti, PhD role: CONTACT phone: 0382380419 phoneExt: 0039 email: silviapaola.caminiti@unipv.it lat: 45.19205 lon: 9.15917 hasResults: False
nctId: NCT06278805 id: ayk22 briefTitle: Adaptation and Validation of the LUNS for Use in Turkey. overallStatus: RECRUITING date: 2024-03-01 date: 2024-12-01 date: 2025-02-01 date: 2024-02-26 date: 2024-04-11 name: Uşak University class: OTHER name: Ankara University name: Istanbul University briefSummary: According to the most up-to-date knowledge, there is no Turkish comprehensive and validated instrument to assess stroke survivors' unmet needs in the longer term. So, this study aims to translate and adapt the LUNS into Turkish and examine its psychometric properties in survivors living at home after a stroke.
- The Turkish Longer-term Unmet Needs after Stroke Questionnaire (T-LUNS) is a valid tool for assessing the unmet needs of stroke patients in the Turkish population. conditions: Stroke conditions: Disability Physical conditions: Quality of Life studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 110 type: ESTIMATED name: The reliability and validity study of the T-LUNS measure: The Turkish Longer-term Unmet Needs after Stroke Questionnaire (T-LUNS) measure: The Stroke Impact Scale 3.0 (SIS) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Usak status: RECRUITING city: Uşak zip: 64200 country: Turkey name: Ali Y Karahan role: CONTACT phone: +905386921934 email: ali.karahan@usak.edu.tr lat: 38.67351 lon: 29.4058 hasResults: False
nctId: NCT06278792 id: Z-2021104 briefTitle: Readily Available Urinary Sodium Analysis in Patients With Acute Decompensated Heart Failure acronym: EASY-HF overallStatus: COMPLETED date: 2022-03-07 date: 2023-07-12 date: 2024-01-05 date: 2024-02-26 date: 2024-02-26 name: Ziekenhuis Oost-Limburg class: OTHER name: Fund for Scientific Research, Flanders, Belgium briefSummary: The goal of this clinical trial is to compare physician-guided (SOC) versus nurse-led natriuresis-guided diuretic therapy in patients with acute decompensated heart failure (ADHF). The main questions it aims to answer are:
Researchers will compare SOC versus nurse-led diuretic titration to see if there is a difference in natriuresis after 48 hours. conditions: Acute Decompensated Heart Failure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The EASY-HF study was a single-centre, randomized, open-label study comparing standard of care (SOC) diuretic management at the treating physician's discretion with a nurse-led natriuresis-guided protocol in patients with ADHF. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: All physicians were blinded for the spot urinary sodium measurements. Additionally, while urine was collected for the first 48 h in both groups, the analysis was only performed afterwards. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 60 type: ACTUAL name: Diuretic protocol name: Standard of Care measure: Urinary sodium excretion after 48 hours measure: Urinary output after 48 hours measure: Urinary sodium excretion on daily base measure: Urinary output on daily base measure: Achievement of decongestion measure: Diuretic dose measure: User-friendliness device and protocol measure: Weight measure: Number of participants with need for heart failure rehospitalization measure: Rate of all-cause mortality measure: Length of hospital stay measure: Number of participants with severe hypotension measure: Number of participants with abnormal blood parameters sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ziekenhuis Oost-Limburg AV city: Genk state: Limburg zip: 3600 country: Belgium lat: 50.965 lon: 5.50082 hasResults: False
nctId: NCT06278779 id: X23-0311 briefTitle: Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression acronym: TREK overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-04 date: 2027-04 date: 2024-02-26 date: 2024-03-13 name: The George Institute class: OTHER name: The University of New South Wales briefSummary: The goal of this study is to compare the effectiveness of two formulations of ketamine - Spravato® and racemic ketamine - in people with treatment-resistant depression (TRD). The main questions it aims to answer are: